Efficacy and Safety of Luspatercept in Patients Enrolled in the BELIEVE Trial: Data from the Phase 3b Long-Term Rollover Study
Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Sujit Sheth(Columbia University Irving Medical Center), Pencho Georgiev(University Multipurpose Hospital for Active Treatment "Sveti Georgi"), Natalia Holot(Bristol-Myers Squibb (United States)), Kevin H.M. Kuo(University Health Network), Yinzhi Lai(Bristol-Myers Squibb (United States)), Alì Taher(American University of Beirut Medical Center), Wen‐Ling Kuo(Chang Gung University), Vip Viprakasit(Siriraj Hospital), Luciana Moro Bueno(Bristol-Myers Squibb (Switzerland)), Loyse Felber Medlin(Bristol-Myers Squibb (Switzerland)), Valérie Vilmont(Bristol-Myers Squibb (Switzerland))
Cited by 1
Related Papers
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Thalassaemia
|The Lancet|2017|763
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
|Haematologica|2014|389
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320